TG Therapeutics

Yahoo Finance • 19 days ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of contin... Full story

Yahoo Finance • 20 days ago

TG Therapeutics Breaks Above 200-Day Moving Average - Bullish for TGTX

In trading on Monday, shares of TG Therapeutics Inc (Symbol: TGTX) crossed above their 200 day moving average of $34.34, changing hands as high as $35.07 per share. TG Therapeutics Inc shares are currently trading up about 8% on the day.... Full story

Yahoo Finance • last month

CXW Makes Bullish Cross Above Critical Moving Average

In trading on Thursday, shares of CoreCivic Inc (Symbol: CXW) crossed above their 200 day moving average of $20.91, changing hands as high as $21.45 per share. CoreCivic Inc shares are currently trading up about 4.5% on the day. The char... Full story

Yahoo Finance • last month

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosi... Full story

Yahoo Finance • last month

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal an... Full story

Yahoo Finance • last month

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Inves... Full story

Yahoo Finance • last month

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.... Full story

Yahoo Finance • last month

Stocks making the biggest moves midday: Alphabet, Bruker, Sprinklr, Dollar Tree & more

Check out the companies making the biggest moves midday: Bruker – The diagnostics solutions stock dropped more than 11% after it announce the sale of $600 million in convertible stocks. The decline puts Bruker on pace for its biggest one-d... Full story

Yahoo Finance • last month

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under... Full story

Yahoo Finance • 2 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, bein... Full story

Yahoo Finance • 2 months ago

TG Therapeutics files automatic mixed securities shelf

* TG Therapeutics (NASDAQ:TGTX [https://seekingalpha.com/symbol/TGTX]) filed automatic mixed securities shelf. * Filing [https://seekingalpha.com/filing/10286774] MORE ON TG THERAPEUTICS * TG Therapeutics: Strong Execution Tempered... Full story

Yahoo Finance • 2 months ago

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

We recently published 10 Stocks Bleeding Early. TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the companies that stood stronger last week. TG Therapeutics fell for a third day on Monday, shedding 18 percent to close at $28.72 apiece as in... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...

Total Revenue: $141.1 million for Q2 2025. US Net Product Revenue: $138.8 million, a 91% increase year-over-year. License, Milestone, and Royalty Revenue: $2.3 million for the quarter. Total Operating Expenses (OpEx): Approximately $71 mil... Full story

Yahoo Finance • 2 months ago

TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform

Investing.com - TG Therapeutics (NASDAQ:TGTX) shares dropped 14% after the company reported second-quarter Briumvi sales that met analyst expectations but failed to impress investors. According to InvestingPro data, the stock remains under... Full story

Yahoo Finance • 2 months ago

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings. What Happened TG Therapeutics reported second-quarter earnings per share of 17 cents, up fro... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Figma, Joby Aviation, CommScope, Wayfair & more

Check out the companies making the biggest moves midday: Figma — The design company tumbled 22%, giving back a chunk of its IPO gains from last week. Figma began trading at the New York Stock Exchange on Thursday, with the stock more than... Full story

Yahoo Finance • 2 months ago

TG Therapeutics falls after Q2 miss despite guidance raise

[Close up image of wooden cubes with alphabet Q2 on office desk.] mohd izzuan TG Therapeutics (NASDAQ:TGTX [https://seekingalpha.com/symbol/TGTX]) shares lost ~18% on Monday after the Morrisville, North Carolina-based biotech fell short o... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance

TG THERAPEUTICS INC (NASDAQ:TGTX [https://www.chartmill.com/stock/quote/TGTX]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company's revenue and earnings per share... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Inc. Q2 Income Rises

(RTTNews) - TG Therapeutics Inc. (TGTX) released a profit for its second quarter that Increases, from last year The company's earnings came in at $28.18 million, or $0.17 per share. This compares with $6.87 million, or $0.04 per share, l... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday... Full story